EpiBiologics Demonstrates Innovative Protein Degradation Capabilities
EpiBiologics, a pioneering company in tissue-selective extracellular protein degradation, is set to present vital new data showcasing the unique features of its EpiTAC platform. These presentations will occur at two prominent scientific meetings: the 16th Annual PEGS Europe conference and the 2024 Antibody Engineering and Therapeutics US conference.
Shyra Gardai, Ph.D., Chief Scientific Officer at EpiBiologics, expressed excitement about the findings, emphasizing their potential therapeutic benefits. This research demonstrates how these advancements are not just relevant to oncology, but also hold promise for treating immune disorders, which are critical areas of medical need.
The EpiTAC bispecific antibodies function by utilizing cell-surface degrader receptors that are prevalent in diseased tissues. This selectivity allows for the targeted degradation of membrane and extracellular proteins. Recent data illustrates that EpiTACs can effectively eliminate target proteins from diseased tissues while preserving the surrounding healthy tissues, which enhances their efficacy as therapeutic agents.
Key Presentation Highlights from EpiBiologics
- By choosing degrader receptors that are enriched in disease tissues, EpiBiologics has shown that its EGFR-targeting EpiTAC antibody can promote enhanced anti-tumor activity while maintaining normal tissue function.
- The EGFR EpiTAC facilitates effective degradation of EGFR regardless of mutations, offering a promising treatment avenue for a wide range of patients suffering from non-small cell lung cancer (NSCLC) and other cancers connected to EGFR.
- In autoimmune applications, EpiTACs allow for degradation specifically localized to T regulatory cells, enhancing the effectiveness of therapies that usually impact both additive and inhibitory immune cells.
- The EpiTAC platform successfully addresses disease-causing GPCRs, highlighting its versatility in treating a variety of diseases, including pain management and various autoimmune and inflammatory conditions.
Dr. Ann Lee-Karlon, President and CEO of EpiBiologics, articulated her enthusiasm regarding their achievements this year. The company has made significant strides, including progressing a targeted EGFR program towards clinical application and refining its approach to degrade GPCRs, known for their complexity in drug development. She noted the importance of expanding the capabilities of their EpiTAC platform to tackle a broader array of diseases while advancing their therapeutic pipeline.
Details of Upcoming Oral Presentations
The forthcoming presentations will cover the innovative aspects and breakthroughs achieved in the field of protein degradation:
16th Annual PEGS Europe
Title: "EpiTACs as a Bispecific Antibody Platform for Degrading Disease-Driving Extracellular Targets"
Date & Time: Wednesday, November 6, 11:15 a.m. CET
Presenter: Shyra Gardai, Ph.D.
2024 Antibody Engineering & Therapeutics US
Title: "EpiTACs: A Novel Bispecific Antibody Approach to Targeting Disease-Driving Proteins"
Date & Time: Monday, December 16, 4:45 p.m. PT
Presenter: Shyra Gardai, Ph.D.
About EpiBiologics
EpiBiologics is dedicated to developing a next-generation protein degradation platform that specifically targets extracellular proteins responsible for diseases. With its roots in the groundbreaking research of Dr. Jim Wells from UCSF, the company’s EpiTAC platform operates as a modular bispecific antibody system designed for targeted degradation in a tissue-specific manner. Through preclinical data, EpiBiologics aims to validate its innovative approach as it strides towards clinical applications. The company is headquartered in the San Francisco Bay Area and is backed by notable investors committed to advancing cutting-edge therapeutic solutions across various fields, including oncology, immunology, neurodegeneration, and metabolism.
Frequently Asked Questions
What is EpiBiologics known for?
EpiBiologics specializes in tissue-selective extracellular protein degradation, focusing on developing innovative therapies through its EpiTAC platform.
What are the key advantages of the EpiTAC platform?
The EpiTAC platform enables targeted degradation of disease-driving proteins specifically in diseased tissues, enhancing therapeutic efficacy while sparing healthy tissues.
What type of diseases can EpiTACs address?
EpiTACs have potential applications in oncology, autoimmune disorders, and various diseases involving GPCRs, expanding the range of treatable conditions.
When and where will the presentations take place?
The presentations will take place at the 16th Annual PEGS Europe conference on November 6 and the 2024 Antibody Engineering & Therapeutics US conference on December 16.
Who will present at the conferences?
Shyra Gardai, Ph.D., Chief Scientific Officer of EpiBiologics, will be the presenter for both conferences, showcasing the advancements of the EpiTAC platform.
